Galileo Research S.r.L's allogeneic stem cell therapy mimics natural killer cells to stimulate tumor cell apoptosis, but does not attack healthy cells. The off-the-shelf therapy could have broader activity against cancer than allogeneic vaccines in development. But first, the biotech needs to raise $8-$10 million to support a Phase II trial in advanced ovarian cancer.

Galileo's TALL-104 is an irradiated, non-proliferating, clonal T cell line, with MHC non-restricted killer cell activity against tumors.